IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Shenzhen Dobot 02432.HK	Advanced hardware and software	18.8-20.8	200	4,202	2024/12/18	Data is not available	2024/12/23
Minieye Tec 02431.HK	Application Software	17-20.2	200	4,081	2024/12/20	2024/12/24	2024/12/27
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	2024/12/27	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	2024/12/27	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	2024/12/27	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Shenzhen Dobot
02432.HK

Advanced hardware and software

18.8-20.8

200

4,202

2024/12/18

Data is not available

2024/12/23

Minieye Tec
02431.HK

Application Software

17-20.2

200

4,081

2024/12/20

2024/12/24

2024/12/27

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

2024/12/27

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

2024/12/27

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

2024/12/27

2024/12/30

Summary

Founded in 2010, we are a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer-associated complications, cancer and age- related ophthalmologic diseases. We have designed and developed a pipeline of seven clinical-stage drug candidates, including our Core Product M701, a recombinant BsAb for which we are currently conducting a Phase II clinical trial in treating malignant ascites (MA) and a Phase Ib/II clinical trial in treating malignant pleural effusion (MPE), and six other drug candidates at various clinical stages. We are currently developing M701 primarily as a palliative care for MA and MPE, which are severe complications of cancer where fluids build up in the abdominal or chest cavity of cancer patients, and not for the treatment for cancer itself. WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP OR MARKET OUR CORE PRODUCT OR ANY OF OUR PIPELINE PRODUCTS. Pipeline of Drug Candidates We have designed and developed a pipeline of seven clinical-stage drug candidates. Our R&D efforts focus on the development of BsAbs. BsAbs are antibodies that bind to two different targets at once. As part of our immune system, our bodies produce protective proteins called antibodies in response to antigen stimulation. Natural antibodies are monospecific antibodies that only bind to a single antigen. Imitating natural antibodies, pharmaceutical companies developed artificial monospecific antibodies that also bind to a single antigen. Their mechanism of action is relatively straightforward: they specifically identify and bind to a particular antigen (protein). BsAbs, on the other hand, are designed to bind to two different targets simultaneously. This allows for relatively complex therapeutic mechanisms. For example, in addition to carrying out the typical functions of monospecific antibodies, one arm of the BsAb can bind to a cancer cell either floating in the abdominal or chest cavity of a cancer patient or forming tumor in a cancer patient, while the other arm binds to a T cell, a type of immune cell. This can bring the immune cells into close proximity with the cancer cells and stimulate the immune response against the floating cancer cells to manage MA or MPE or the tumor-forming cancer cells to fight tumors. However, due to the artificial modifications required to enable binding to two different targets, BsAbs can become structurally complex. This complexity can make them more difficult and costly to produce than traditional, monospecific antibodies. The future trends of China’s BsAb drug market include: (a) the development of manufacturing technologies for BsAbs. The BsAb development has long been hampered by manufacturing related challenges, such as product instability, low expression yields and immunogenicity. Simplifying the structure and production procedures is the key to designing an ideal BsAb platform moving forward; (b) the expansion of indications for BsAbs, as BsAbs have the potential to go beyond the treatment of tumors and serve as an important modality for the treatment of other disease types such as inflammatory diseases; and (c) the proactive engagement of leading domestic pharmaceutical companies in the research and development of BsAbs drugs. Source: YZY Biopharma-B (02496) Prospectus (IPO Date : 2023/09/13)
Listing Market	MAIN
Industry	Biotechnology - Pharmaceuticals
Background	H Shares
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Yuan Qian & Associates (Total share: 28.68%); (H share: 1.20%) CSPC NBP Pharmaceutical Co., Ltd. (Total share: 26.43%); (H share: 45.97%) Wen Zhicheng (Total share: 8.71%); (H share: 10.61%) Guo Hongwei & Associates (Total share: 6.99%); (H share: 7.29%) CDH Growth Fund III (USD Parallel), L.P. (Total share: 4.08%); (H share: 7.10%) Hainan Boyou Enterprise Management Consulting Center (Limited Partnership) (Total share: 3.94%); (H share: 6.84%) Ningbo Meishan Bonded Port Area Guangrui Hongxiang Equity Investment Partnership (Limited Partnership) (Total share: 3.71%); (H share: 6.46%)
Directors	Yuan Qian (Co-Founder and Non-Executive Director) Zhou Hongfeng (Co-Founder and Non-Executive Director) Zhou Pengfei (Co-Founder and Chairman and Chief Executive Officer and Executive Director) Hui Xiwu (Non-Executive Director) Liang Qian (Non-Executive Director) Pang Zhenhai (Non-Executive Director) Xie Shouwu (Non-Executive Director) Wen Zhicheng (Non-Executive Director) Chen Bin (Independent Non-Executive Director) Cheng Bin (Independent Non-Executive Director) Deng Yuezhen (Independent Non-Executive Director) Fu Lili (Independent Non-Executive Director)
Company Secretary	Lai Janette Tin Yun Zheng Jianhua
Principal Bankers	China CITIC Bank International Limited China Merchants Bank Industrial Bank Co., Ltd
Solicitors	Cooley HK Dentons Law Offices
Auditors	Deloitte Touche Tohmatsu
Registered Office	5th Floor, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.yzybio.com
Email Address	info@yzybio.com
Tel No	(86 27) 8266-8988
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates